Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

2.

Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.

Tan D, Chen KE, Khoo T, Walker AM.

Cancer Lett. 2011 Nov 1;310(1):101-8. doi: 10.1016/j.canlet.2011.06.014. Epub 2011 Jun 25.

PMID:
21775057
3.

Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.

Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY.

Breast Cancer Res Treat. 2008 Sep;111(2):241-50. Epub 2007 Oct 23.

PMID:
17955362
4.

Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation.

Perrot-Applanat M, Gualillo O, Buteau H, Edery M, Kelly PA.

J Cell Sci. 1997 May;110 ( Pt 9):1123-32.

5.

Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.

Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M.

Cell Death Differ. 2010 Dec;17(12):1867-81. doi: 10.1038/cdd.2010.53. Epub 2010 May 28.

6.
7.

Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.

Xu C, Langenheim JF, Chen WY.

Breast Cancer Res Treat. 2012 Jul;134(1):157-69. doi: 10.1007/s10549-012-1954-3. Epub 2012 Jan 22.

PMID:
22270933
8.

Implication of alpha4 phosphoprotein and the rapamycin-sensitive mammalian target-of-rapamycin pathway in prolactin receptor signalling.

Boudreau RT, Sangster SM, Johnson LM, Dauphinee S, Li AW, Too CK.

J Endocrinol. 2002 Jun;173(3):493-506.

9.

The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.

Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE, Liu DX.

Int J Oncol. 2012 Dec;41(6):2285-95. doi: 10.3892/ijo.2012.1660. Epub 2012 Oct 15.

PMID:
23064471
10.

Expression of prolactin and its receptor in human breast carcinoma.

Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV.

Endocrinology. 1997 Dec;138(12):5555-60.

PMID:
9389544
12.

Prolactin (PRL) and prolactin receptor (PRLR) genes and their role in poultry production traits.

Wilkanowska A, Mazurowski A, Mroczkowski S, Kokoszyński D.

Folia Biol (Krakow). 2014;62(1):1-8. Review.

PMID:
24745142
13.

CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.

Lim JH, Kim TY, Kim WH, Park JW.

Breast Cancer Res Treat. 2011 Nov;130(1):19-27. doi: 10.1007/s10549-010-1274-4. Epub 2010 Dec 3.

PMID:
21128111
14.

Defective prolactin signaling impairs pancreatic β-cell development during the perinatal period.

Auffret J, Freemark M, Carré N, Mathieu Y, Tourrel-Cuzin C, Lombès M, Movassat J, Binart N.

Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1309-18. doi: 10.1152/ajpendo.00636.2012. Epub 2013 Sep 24.

15.

Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.

Damiano JS, Wasserman E.

Clin Cancer Res. 2013 Apr 1;19(7):1644-50. doi: 10.1158/1078-0432.CCR-12-0138. Epub 2013 Mar 20. Review.

16.

From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.

Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F.

J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):147-56. doi: 10.1007/s10911-008-9074-8. Epub 2008 Feb 2. Review.

PMID:
18246318
17.

Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.

Thomas LN, Merrimen J, Bell DG, Rendon R, Goffin V, Too CK.

Prostate. 2014 May;74(7):732-42. doi: 10.1002/pros.22793. Epub 2014 Feb 24.

PMID:
24615730
18.

Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.

Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, Hiltunen M.

Prog Neurobiol. 2013 Jul-Aug;106-107:33-54. doi: 10.1016/j.pneurobio.2013.06.002. Epub 2013 Jul 1. Review.

PMID:
23827971
19.

Characterization of multiple first exons in murine prolactin receptor gene and the effect of prolactin on their expression in the choroid plexus.

Tabata H, Kobayashi M, Ikeda JH, Nakao N, Saito TR, Tanaka M.

J Mol Endocrinol. 2012 Feb 29;48(2):169-76. doi: 10.1530/JME-11-0122. Print 2012 Apr.

20.

The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.

Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ.

Cell Death Differ. 2010 Apr;17(4):666-76. doi: 10.1038/cdd.2009.149. Epub 2009 Oct 16.

Items per page

Supplemental Content

Write to the Help Desk